产品名称
抗-CD133（Prominin-1）抗体，克隆17A6.1, clone 17A6.1, from mouse
biological source
mouse
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
17A6.1, monoclonal
species reactivity
human
technique(s)
immunocytochemistry: suitable
western blot: suitable
isotype
IgG2aκ
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Quality Level
Gene Information
human ... PROM1(8842)
Analysis Note
通过重组Prominin-1的蛋白质印迹法进行评估。
蛋白质印迹分析：1 µg/mL的该抗体检测到2.5 µg重组Prominin-1蛋白。
蛋白质印迹分析：1 µg/mL的该抗体检测到2.5 µg重组Prominin-1蛋白。
Application
使用该小鼠单克隆抗CD133（Prominin-1）抗体（克隆17A6.1，目录号:编号MAB4399-I）检测CD133。经验证可用于免疫细胞化学。
免疫细胞化学分析：一个代表性批次以1:50稀释度在U251细胞中检测到CD133。
Biochem/physiol Actions
克隆17A6.1通过蛋白质印迹法检测重组CD133（Prominin-1），还通过免疫细胞化学检测U251细胞中的CD133（Prominin-1）。
General description
Prominin-1（UniProt：O43490；也称为抗原AC133，Prominin样蛋白质1，CD133）由人的PROM1（也称为PROML1，MSTP061）基因（基因ID：8842）编码。CD133（Prominin-1）是多通道细胞表面糖蛋白，在细胞分化、增殖和凋亡中起作用。它结合含胆固醇的质膜微区中的胆固醇，并可能在上皮细胞的顶质膜的组织中起作用。在视网膜早期发育过程中，CD133充当盘形态发生的关键调节因子。已知PROM1基因缺陷会导致色素性视网膜炎、视锥杆细胞营养不良和视网膜黄斑营养不良2。已经报道了几种癌细胞类型中较高水平的CD133，包括各种白血病、视网膜母细胞瘤、胶质母细胞瘤和肾癌。在胰腺癌、胃癌、结直肠癌和肝细胞癌中也观察到更高水平的CD133。它也被认为是成年小肠中干细胞的标志物，这些干细胞易于转化为保留一部分突变Prom1+肿瘤细胞的肿瘤。（参考文献：Zhu, L., et al. (2009).Nature 477（7229）；603-607）。
观测分子量〜97 kDa；计算分子量97.2 kDa。在某些裂解物中可以观察到未鉴定的条带。
Immunogen
GST标记的重组片段，对应于人CD133（Prominin-1）N末端区域的77个氨基酸。
Other Notes
浓度：请参考特定批次的数据表。
Physical form
形式：纯化
未找到合适的产品？
试试我们的产品选型工具.
存储类别
12 - Non Combustible Liquids
wgk
WGK 1
Cong Li et al.
Oncology letters, 22(1), 499-499 (2021-05-14)
Cancer stem cells (CSCs) and epithelial mesenchymal transition (EMT) markers are considered useful indicators associated with metastasis and prognosis of colorectal cancers (CRCs). However, only a few studies have focused on the expression of these useful markers in metastases. Metastasectomy
Naoki Yamashita et al.
Scientific reports, 12(1), 1473-1473 (2022-01-29)
Cancer stem cells (CSCs) are major contributors to the malignant transformation of cells because of their capacity for self-renewal. Aldehyde dehydrogenase1A1 (ALDH1A1) and CD133 are promising candidate of CSC markers in non-small cell lung cancer (NSCLC). Furthermore, TP53 is frequently
Carmen Gil-Gas et al.
Cancers, 15(22) (2023-11-25)
Breast cancer is the leading cause of death among females in developed countries. Although the implementation of screening tests and the development of new therapies have increased the probability of remission, relapse rates remain high. Numerous studies have indicated the
Xiaofei Wang et al.
Oncology reports, 40(1), 241-251 (2018-05-12)
Insufficient radiofrequency ablation (iRFA) often leads to residual hepatocellular carcinoma (HCC) progression. However, the mechanism is still poorly understood. In the present study, we demonstrated that LC3B protein expression levels were significantly increased in the residual hepatocellular carcinoma cells after
Yi Sui et al.
British journal of cancer, 125(7), 1003-1015 (2021-07-12)
Metastasis is the major cause of treatment failure and cancer-related deaths in prostate cancer (PCa) patients. Our previous study demonstrated that a CD44+ subpopulation isolated from PCa cells or tumours possesses both stem cell properties and metastatic potential, serving as
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持